As of November 4, 2026, 10x Genomics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on November 2, 2026, naming 1 appointment. The latest filing names Joseph Gilliam, appointed (Form 8-K, November 2, 2026).
Sell to companies like 10x Genomics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
10x Genomics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-11-02. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as 10x Genomics, Inc. files it.
Also on the record for 10x Genomics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 7, 2026 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 5.22% of the class | 5%+ stakes | Source |
| September 8, 2026 | Stake report, Schedule 13G, by T. Rowe Price Associates, Inc. | 11.7% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 8.56% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.24% of the class | 5%+ stakes | Source |
| April 28, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.93% of the class | 5%+ stakes | Source |
| March 25, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 24, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 15.6% of the class | 5%+ stakes | Source |
| January 8, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 10.8% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by Amova Asset Management Americas, Inc. | 4.7% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 8.1% of the class | 5%+ stakes | Source |
| November 4, 2025 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 10.39% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs 10x Genomics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on 10x Genomics, Inc. and the records around it.
10x Genomics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Amova Asset Management Americas, Inc. also filed stake reports on 3 other companies: Ibotta, Inc. (Feb 2026), Arcturus Therapeutics Holdings Inc. (Nov 2025)
- Sumitomo Mitsui Trust Group, Inc. also filed stake reports on 7 other companies: Arcturus Therapeutics Holdings Inc. (Oct 2026), GCM Grosvenor Inc. (Apr 2026), Ibotta, Inc. (Feb 2026)
- ARK Investment Management LLC also filed stake reports on 20 other companies: Twist Bioscience Corp (Sep 2026), 908 Devices Inc. (Aug 2026), Beam Therapeutics Inc. (Aug 2026)
Watch 10x Genomics, Inc.
Get an email when 10x Genomics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on 10x Genomics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on 10x Genomics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on 10x Genomics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 20 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-02 | In | 8-K, 2026-11-02 |
New leaders reset buying decisions — get the Full Report on 10x Genomics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at 10x Genomics, Inc., with the record behind each one.
Find candidates like senior executive at 10x Genomics, Inc.Every change, in the filing's words
Appointed: Joseph Gilliam
On October 30, 2026, Mr. Gilliam was appointed Chair of the Audit Committee of the Board of Directors, for which he shall receive an annual retainer of $25,000 (prorated as necessary).
- On October 28, 2026, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors of 10x Genomics, Inc. (the "Company") appointed Ansuman Satpathy and Joseph Gilliam to the Board of Directors as Class III directors effective immediately, each with a term expiring at the Company's 2028 annual meeting of stockholders or until his successor is duly elected and qualified or until his earlier death, resignation, disqualification or removal.
- Dr. Satpathy has served as Associate Professor of Pathology and Immunology at Stanford University since April 2024 and a venture partner at Wing Venture Capital since November 2021.
- He has been director of the Stanford Center for Immunotherapy Design since April 2024, co-director of the Parker Institute for Cancer Immunotherapy at Stanford University since April 2024, and co-director of the Immunotherapy Program in the Stanford Cancer Institute since April 2024.
- He previously served as an Assistant Professor at Stanford University from July 2019 through April 2024.
- Dr. Satpathy is a co-founder of four private life sciences companies focused on data-driven and AI-enabled approaches to drug discovery in oncology and immunology - Immunai, Cartography Biosciences, Santa Ana Bio and Arpelos Biosciences - and serves on the boards of a number of private life sciences companies.
Tools for this story
Each opens in a new tab, filled in for 10x Genomics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.